Generate Biomedicines, Inc. (GENB) fair value analysis
Nasdaq · Updated 2026-10-19
GENB price how computed
Valuation status
No fair-value estimate yetGENB has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for GENB yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $12.09
- Sector
- Healthcare
- 12-month range
- $12.09–$16.50
- Market cap
- $1.55B
- From 52-week high
- -26.7%
- Shares outstanding
- 128M
- Rank in Healthcare by quality score
- #187 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Generate Biomedicines, Inc. is a biotechnology company that develops protein therapeutics using computational biology and machine learning technologies to design novel medicines. The company is based in the United States and operates in the healthcare sector, focusing on the discovery and development of therapeutic proteins for various diseases.
GENB currently ranks #187 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.55B
- Revenue (TTM)
- $32.5M
- Net margin
- -685.9%
- Gross margin
- 100.0%
- Debt / equity
- 0.14
- Shares outstanding
- 128M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 26 · oversold
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 2 quarters vs consensus
- 0 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-8.3%)
2026-03 ▼ miss (-109.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $27
- Target vs last price
- +123.3%
What our data shows for GENB
- Shares are trading in the lower third of their 12-month price range of $12.09–$16.50.
- The 14-day relative strength index sits at an oversold 26.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- GENB's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the GENB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for GENB show a shift in momentum this week, with the RSI zone moving from neutral to oversold territory. The stock's valuation verdict remains awaiting full valuation as of the latest assessment.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is GENB stock undervalued?
TickrTrends has no fair-value estimate for GENB yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is GENB's TickrTrends verdict?
GENB is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does GENB compare to other Healthcare stocks?
GENB ranks #187 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is GENB overbought or oversold?
GENB's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does GENB report earnings next?
GENB's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does GENB usually beat earnings estimates?
Over its last 2 reported quarters GENB beat the consensus estimate 0 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about GENB?
Of 6 analysts covering GENB, 6 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $27 (+123.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.